Cargando…

Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury

Liraglutide (Lir) is a glucagon-like peptide-1 receptor agonist that lowers blood sugar and reduces myocardial infarct size by improving endothelial cell function. However, its mechanism has not yet been clarified. Unfolded protein response (UPR) plays an important role in the pathogenesis of myocar...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chong, Liu, Yong, He, Jing, Mu, Rong, Di, Yanbo, Shen, Na, Liu, Xuan, Gao, Xiao, Wang, Jinhui, Chen, Tie, Fang, Tao, Li, Huanming, Tian, Fengshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664686/
https://www.ncbi.nlm.nih.gov/pubmed/31396081
http://dx.doi.org/10.3389/fphar.2019.00789
_version_ 1783439935109332992
author Liu, Chong
Liu, Yong
He, Jing
Mu, Rong
Di, Yanbo
Shen, Na
Liu, Xuan
Gao, Xiao
Wang, Jinhui
Chen, Tie
Fang, Tao
Li, Huanming
Tian, Fengshi
author_facet Liu, Chong
Liu, Yong
He, Jing
Mu, Rong
Di, Yanbo
Shen, Na
Liu, Xuan
Gao, Xiao
Wang, Jinhui
Chen, Tie
Fang, Tao
Li, Huanming
Tian, Fengshi
author_sort Liu, Chong
collection PubMed
description Liraglutide (Lir) is a glucagon-like peptide-1 receptor agonist that lowers blood sugar and reduces myocardial infarct size by improving endothelial cell function. However, its mechanism has not yet been clarified. Unfolded protein response (UPR) plays an important role in the pathogenesis of myocardial ischemia-reperfusion injury. It determines the survival of cells. Endoplasmic reticulum position protein homologue 2 (CNPY2) is a novel initiator of UPR that also participates in angiogenesis. To this extent, the current study further explored whether Lir regulates angiogenesis through CNPY2. In our article, a hypoxia/reoxygenation (H/R) injury model of human umbilical vein endothelial cells (HUVECs) was established and the effect of Lir on HUVECs was first evaluated by the Cell Counting Kit-8. Endothelial tube formation was used to analyze the ability of Lir to induce angiogenesis. Subsequently, the effect of Lir on the concentrations of hypoxia-inducible factor 1α (HIF1α), vascular endothelial growth factor (VEGF), and CNPY2 was detected by enzyme-linked immunosorbent assay. To assess whether Lir regulates angiogenesis through the CNPY2-initiated UPR pathway, the expression of UPR-related pathway proteins (CNPY2, GRP78, PERK, and ATF4) and angiogenic proteins (HIF1α and VEGF) was detected by reverse transcription-polymerase chain reaction and Western blot. The results confirmed that Lir significantly increased the expression of HIF1α and VEGF as well as the expression of CNPY2-PERK pathway proteins in HUVECs after H/R injury. To further validate the experimental results, we introduced the PERK inhibitor GSK2606414. GSK2606414 was able to significantly decrease both the mRNA and protein expression of ATF4, HIF1α, and VEGF in vascular endothelial cells after H/R injury. The effect of Lir was also inhibited using GSK2606414. Therefore, our study suggested that the CNPY2-PERK pathway was involved in the mechanism of VEGF expression after H/R injury in HUVECs. Lir increased the expression of VEGF through the CNPY2-PERK pathway, which may promote endothelial cell angiogenesis and protect HUVEC from H/R damage.
format Online
Article
Text
id pubmed-6664686
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66646862019-08-08 Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury Liu, Chong Liu, Yong He, Jing Mu, Rong Di, Yanbo Shen, Na Liu, Xuan Gao, Xiao Wang, Jinhui Chen, Tie Fang, Tao Li, Huanming Tian, Fengshi Front Pharmacol Pharmacology Liraglutide (Lir) is a glucagon-like peptide-1 receptor agonist that lowers blood sugar and reduces myocardial infarct size by improving endothelial cell function. However, its mechanism has not yet been clarified. Unfolded protein response (UPR) plays an important role in the pathogenesis of myocardial ischemia-reperfusion injury. It determines the survival of cells. Endoplasmic reticulum position protein homologue 2 (CNPY2) is a novel initiator of UPR that also participates in angiogenesis. To this extent, the current study further explored whether Lir regulates angiogenesis through CNPY2. In our article, a hypoxia/reoxygenation (H/R) injury model of human umbilical vein endothelial cells (HUVECs) was established and the effect of Lir on HUVECs was first evaluated by the Cell Counting Kit-8. Endothelial tube formation was used to analyze the ability of Lir to induce angiogenesis. Subsequently, the effect of Lir on the concentrations of hypoxia-inducible factor 1α (HIF1α), vascular endothelial growth factor (VEGF), and CNPY2 was detected by enzyme-linked immunosorbent assay. To assess whether Lir regulates angiogenesis through the CNPY2-initiated UPR pathway, the expression of UPR-related pathway proteins (CNPY2, GRP78, PERK, and ATF4) and angiogenic proteins (HIF1α and VEGF) was detected by reverse transcription-polymerase chain reaction and Western blot. The results confirmed that Lir significantly increased the expression of HIF1α and VEGF as well as the expression of CNPY2-PERK pathway proteins in HUVECs after H/R injury. To further validate the experimental results, we introduced the PERK inhibitor GSK2606414. GSK2606414 was able to significantly decrease both the mRNA and protein expression of ATF4, HIF1α, and VEGF in vascular endothelial cells after H/R injury. The effect of Lir was also inhibited using GSK2606414. Therefore, our study suggested that the CNPY2-PERK pathway was involved in the mechanism of VEGF expression after H/R injury in HUVECs. Lir increased the expression of VEGF through the CNPY2-PERK pathway, which may promote endothelial cell angiogenesis and protect HUVEC from H/R damage. Frontiers Media S.A. 2019-07-24 /pmc/articles/PMC6664686/ /pubmed/31396081 http://dx.doi.org/10.3389/fphar.2019.00789 Text en Copyright © 2019 Liu, Liu, He, Mu, Di, Shen, Liu, Gao, Wang, Chen, Fang, Li and Tian http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Chong
Liu, Yong
He, Jing
Mu, Rong
Di, Yanbo
Shen, Na
Liu, Xuan
Gao, Xiao
Wang, Jinhui
Chen, Tie
Fang, Tao
Li, Huanming
Tian, Fengshi
Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
title Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
title_full Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
title_fullStr Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
title_full_unstemmed Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
title_short Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
title_sort liraglutide increases vegf expression via cnpy2-perk pathway induced by hypoxia/reoxygenation injury
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664686/
https://www.ncbi.nlm.nih.gov/pubmed/31396081
http://dx.doi.org/10.3389/fphar.2019.00789
work_keys_str_mv AT liuchong liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT liuyong liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT hejing liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT murong liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT diyanbo liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT shenna liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT liuxuan liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT gaoxiao liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT wangjinhui liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT chentie liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT fangtao liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT lihuanming liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury
AT tianfengshi liraglutideincreasesvegfexpressionviacnpy2perkpathwayinducedbyhypoxiareoxygenationinjury